Trial
NCT03893565
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Colitis, Ulcerative
Intervention
GSK2831781 - Double Blind Phase
Why stopped
The trial was stopped based on the assessment of clinical data.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-04-27